

The Royal Marsden NHS Foundation Trust – Medicines Formulary

NICE register for medicines initiated at the trust.

CG denotes Clinical Guideline

TA denotes Technical Appraisal

For further information about NICE and full guidelines please refer to www.nice.org.uk

	Title	Type and code	Publication date	Action
1.	Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition	(CG32)	February 2006	Implemented at trust
3.	Colon Can. Adjuvant - Capecitabine and oxaliplatin	(TA100)	March 2006	Implemented at trust
4.	Docetaxel in HRPC	(TA101)	June 2006	Implemented at trust
5.	Management of Atrial Fibrillation	(CG36)	June 2006	Implemented at trust
6.	Colorectal Laparoscopic surgery review	(TA105)	August 2006	Implemented at trust
7.	Hepatitis C – Peg interferon and ribavirin	(TA106)	August 2006	Implemented at trust
8.	Breast (early) Trastuzumab	(TA107)	August 2006	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

9.	Breast cancer (early) Docetaxel	(TA109)	September 2006	Implemented at trust
10.	Breast cancer (early) Paclitaxel	(TA108)	September 2006	Implemented at trust
11.	Follicular lymphoma – Rituximab	(TA110)	September 2006	Implemented at trust
12.	Breast (early) hormonal treatments	(TA112)	November 2006	Implemented at trust
13.	Gemcitabine for the treatment of early Breast ca.	(TA116)	January 2007	Implemented at trust
14.	Bevacizumab and cetuximab in metastatic CRC	(TA118)	January 2007	Implemented at trust
15.	Laparoscopic Radical Prostatectomy	(IPG193)	November 2006	Implemented at trust
16.	PDT for advanced/early oesophageal ca.	(IPG200)	December 2006	Implemented at trust
18.	Leukemia (Lymphocytic) – Fludarabine	(TA119)	February 2007	Implemented at trust
20.	MI secondary prevention	(CG48)	May 2007	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

21.	Venous thromboembolism	(CG46)	April 2007	Implemented at trust
22.	Glioma – carmustine implants	(TA121)	July 2007	Implemented at trust
23.	Glioma – temozolomide	(TA121)	July 2007	Implemented at trust
24.	Alteplase for the treatment of acute ischaemic heart disease	(TA122)	July 2007	Implemented at trust
25.	Management of faecal incontinence	(CG49)	June 2007	Implemented at trust
26.	Pemetrexed for the treatment of NSCLC	(TA124)	August 2007	Implemented at trust
27.	Bortezomib for the treatment of multiple myeloma	(TA129)	October 2007	Implemented at trust
28.	Pemetrexed for the treatment of malignant pleural mesothelioma	(TA135)	January 2008	Implemented at trust
29.	Lymphoma (follicular NHL) – rituximab	(TA137)	February 2008	Implemented at trust
30.	Prostate cancer – diagnosis and treatment	(CG58)	February 2008	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

31.	Inadvertent peri-operative hyperthermia	(CG65)	April 2008	Implemented at trust
32.	Epoetin alfa, epoetin beta and darbepoetin alfa for cancer induced anaemia	(TAG142)	May 2008	Implemented at trust
33.	Cetuximab for the treatment of locally advanced SCC of H&N	(TAG 145)	June 2008	Implemented at trust
34.	Erlotinib in NSCLC	(TAG162)	November 2008	Implemented at trust
35.	Metastatic spinal chord compression	(CG75)	November 2008	Implemented at trust
36.	Surgical site infection	(CG74)	October 2008	Implemented at trust
37.	Spinal cord stimulation for chronic pain of neuropathic origin	(TAG159)	October 2008	Implemented at trust
38.	Influenza (prophylaxis) – amantadine, oseltamir and zanamivir	(TAG158)	September 2008	Implemented at trust
39.	Medicines Adherence	(CG76)	January 2009	Implemented at trust
40.	Early and locally advanced Breast ca.	(CG80)	February 2009	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

41.	Advanced Breast ca.	(CG81)	February 2009	Implemented at trust
42.	Influenza –zanamivir, amantadine and oseltamivir (review)	(TAG168)	February 2009	Implemented at trust
43.	Sunitinib for 1 st line treatment of advanced and/or metastatic RCC	(TAG169)	March 2009	Implemented at trust
44.	Type II Diabetes – newer agents	(CG87)	May 2009	Implemented at trust
45.	Cetuximab in combination with FOLFOX	(TAG176)	June 2009	Implemented at trust
46.	Lenalidomide in MM	(TAG171)	June 2009	Implemented at trust
47.	Rituximab in combination with FC in 1 st line CLL	(TAG174)	July 2009	Implemented at trust
48.	Sunitinib in GIST	(TAG179)	September 2009	Implemented at trust
49.	Pemetrexed in NSCLC	(TAG181)	July 2009	Implemented at trust
50.	Cetuximab in H&N ca.	(TAG172)	August 2009	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

51.	Renal Cell Ca.	(TAG178)	August 2009	Implemented at trust
52.	Topotecan in recurrent stage IVb cervical ca.	(TAG183)	October 2010	Implemented at trust
53.	Topotecan (oral) in relapsed SCLC	(TAG184)	November 2010	Implemented at trust
54.	Trabectedin for treatment of advanced STS	(TAG185)	February 2010	Implemented at trust
55.	Venous thrombo embolism reducing the risk	(CG92)	February 2010	Implemented at trust
56.	Chest pain of recent onset	(CG95)	March 2010	Implemented at trust
57.	Unstable angina in NSTEMI	(CG96)	March 2010	Implemented at trust
58.	Pemetrexed maintenance	(TA190)	June 2010	Implemented at trust
59.	Skin Tumours including melanoma	(CSGSTIM)	May 2010	Implemented at trust
60.	Hepatocellular Carcinoma (advanced & metastatic) – Sorafenib 1 st line	(TA189)	May 2010	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

61.	Imatanib for adjuvant GIST	(TA196)	August 2010	Implemented at trust
62.	Denosumab therapy induced bone loss in prostate ca.		July 2010	Implemented at trust
63.	Trastuzumab in GI ca. (HER2+ in combination with Cis/X or Cis/5FU)	(TA208)	November 2010	Implemented at trust
64.	Imatinib in GIST – dose escalation 600mg or 800mg	(TA209)	November 2010	Implemented at trust
65.	Bevacizumab in mCRC (in combination with FOLFOX/XELOX)	(TA212)	December 2010	Implemented at trust
66.	Sedation in children + young people for diagnostic and therapeutic procedures	(CG112)	December 2010	Implemented at trust
67.	Bendamustine 1 st line CLL for patients not suitable for Fludarabine	(TA216)	February 2011	Implemented at trust
68.	Bevacizumab in combination with a taxane for breast Ca	(TA214)	February 2011	Implemented at trust
69.	Azacitidine in line with licensed indication for MDS, AML, CML	(TA218)	March 2011	Implemented at trust
70.	Pazopanib for 1 st line Renal cell carcinoma	(TA215)	February 2011	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

71.	Everolimus in 2 nd line RCC	(TA219)	April 2011	Implemented at trust
72.	Ovarian ca. guidelines	(CG122)	April 2011	Implemented at trust
73.	Lung ca. guidelines	(CG121)	April 2011	Implemented at trust
74.	Romiplostim in chronic ITP	(TA221)	April 2011	Implemented at trust
75.	Erlotinib in maintenance NSCLC	(TA227)	June 2011	Implemented at trust
76.	Rituximab in maintenance follicular lymphoma following response to 1 st line therapy.	(TA226)	June 2011	Implemented at trust
77.	Rituximab as 1 st line maintenance in NHL	(TA226)	June 2011	Implemented at trust
78.	Bortezomib and Thalidomide as 1 st line in MM	(TA228)	July 2011	Implemented at trust
79.	Bivalirudin for treatment of ST segment MI	(TA230)	July 2011	Implemented at trust
80.	Hyperglycaemia in ACS	(CG130)	October 2011	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

81.	Fulvestrant in metastatic Breast ca.	(TA239)	December 2011	Implemented at trust
82.	Anaphylaxis	(CG134)	December 2011	Implemented at trust
83.	Dasatanib , high dose imatanib & nilotinib in CML	(TA241)	January 2012	Implemented at trust
84.	Cetuximab (in combination), Bevacizumab (in combination) and Panatumumab (monotherapy) for treatment of CRC after 1 st line chemotherapy	(TA242)	January 2012	Implemented at trust
85.	Follicular Lymphoma (stage III/IV), rituximab in combination with specific chemotherapy regimens.	(TA243)	January 2012	Implemented at trust
86.	Patient Experiences in Adult NHS Services.	(CG138)	February 2012	Implemented at trust
87.	Dabigatran– for prevention or treatment of stroke and embolism in patients with AF	(TA249)	February 2012	Implemented at trust
88.	Eribulin in metastatic breast	(TA250)	March 2012	Implemented at trust
89.	Dasastanib, nilotinib & imatanib (standard dose) in 1 st line CML	(review of TAG70)	March 2012	Implemented at trust
90.	Rivaroxaban	(TA256)	May 2012	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

91.	Lapatinib ad Trastuzumab in combination with an AI	(TA257)	June 2012	Implemented at trust
92.	Erlotinib	(TA258)	June 2012	Implemented at trust
93.	Rivaroxaban	(TA261)	July 2012	Implemented at trust
94.	Acute upper GI bleeding	(CG141)	June 2012	Implemented at trust
95.	VTE diseases	(CG144)	June 2012	Implemented at trust
96.	Bevacizumab in mBreast ca.	(TA263)	August 2012	Implemented at trust
97.	Neutropenic Sepsis	(CG151)	September 2012	Implemented at trust
98.	Denosumab	(TA265)	October 2012	Implemented at trust
99.	Ipilimumab in melanoma	(TA268)	December 2012	Implemented at trust
100.	Vemurafenib in melanoma	(TA269)	December 2012	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

101.	Vinflunine for urothelial tract carcinoma	(TA272)	January 2013	Implemented at trust
102.	Bevacizumab in combination in ovarian ca.	(TA284)	May 2013	Implemented at trust
103.	Bevacizumab in ovarian, fallopian tube & primary peritoneal ca.	(TA285)	May 2013	Implemented at trust
104.	Familial Breast Cancer	(CG164)	July 2013	Implemented at trust
105.	Dapagliflozin in type II diabetes	(TA288)	July 2013	Implemented at trust
106.	Ruxilitionib in Myelofibrosis	(TA289)	July 2013	Implemented at trust
107.	Rivaroxaban in PE and recurrent VTE	(TA287)	July 2013	Implemented at trust
108.	Myocardial infarction with ST elevation	(CG167)	July 2013	Implemented at trust
109.	Eltombopag in chronic ITP	(TA293)	July 2013	Implemented at trust
110.	Everolimus in combination with exemestane in advanced HER2+ve breast ca	(TA295)	August 2013	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

111.	Crizotinib for previously treated non small cell lung cancer in associated with anaplastic lymphoma kinase infusion gene.	(TA296)	September 2013	Implemented at trust
112.	Bosutinib for previously treated chronic myeloid leukemia	(TA199)	November 2013	Implemented at trust
113.	Intravenous fluid therapy in adults in hospital	(CG174)	December 2013	Implemented at trust
114.	Pixantrone in multiple relapsed refractory aggressive NH B cell lymphoma. Ian Chau to be made aware.	(TA306)	February 2014	Implemented at trust
115.	Clinical guideline for prostate cancer	(CG 175)	January 2014	Implemented at trust
116.	Aflibercept in combination with irinotecan & 5FU (Folfiri) in mCRC following progression with oxaliplatin	(TA307)	March 2014	Implemented at trust
117.	Pemetrexed in maintenance treatment in NSCLC	(TA309)	April 2014	Implemented at trust
118.	Afatanib in EGFR+ve locally advanced or metastatic NSCLC in TKI naïve patients	(TA310)	April 2014	Implemented at trust
119.	Bortezomib +ve. Pre high dose chemotherapy and autologous stem cell transplant.	(TA311)	April 2014	Implemented at trust
120.	Management of atrial fibrillation	(CG180)	June 2014	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

121.	Enzalutamide in relapsed prostate ca. previously treated with docetaxel	(TA316)	July 2014	Implemented at trust
122.	Ipilimumab in previously untreated advanced unresectable melanoma +ve, Melanoma unit aware of guidance and implementation date	(TA319)	July 2014	Implemented at trust
123.	Advanced breast cancer	(update CG81)	July 2014	Implemented at trust
124.	Drug Allergy: Diagnosis & management of drug allergy in adults Children and Young persons.	(CG183)	September 2014	Implemented at trust
125.	Dabrafenib for the treatment of BRAF V600 mutation positive, unresectable, advanced or metastatic melanoma.	(TA321)	October 2014	Implemented at trust
126.	Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142).	(TA323)	November 2014	Implemented at trust
127.	Sipuleucel-T. Treatment of asymptomatic/minimally symptomatic hormone relapsed prostate cancer.	(TA332)	February 2015	Implemented at trust
128.	Axitinib. Treatment of advanced RCC after failure of prior TKI's.	(TA333)	February 2015	Implemented at trust
129.	Rifaxamin. Treatment of hepatic encephalopathy.	(TA337)	March 2015	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

130.	Pomalidomide Relapsed refractory myeloma previously treated with thalidomide & bortezomib.	(TA338)	March 2015	Implemented at trust
131.	Medicines Optimisation: the safe and effective use of medicines to enable best possible outcomes.	(NG5)	March 2015	Implemented at trust
132.	Apixaban for the treatment and secondary prevention of DVT and/or PE.	(TA341)	June 2015	Implemented at trust
133.	Obinutuzumab in combination with chlorambucil for untreated CLL.	(TA343)	June 2015	Implemented at trust
134.	Ofatumumab in combination with chlorambucil or bendamustine for untreated CLL.	(TA344)	June 2015	Implemented at trust
135.	Nintedanib with docetaxel, for adenocarcinoma of locally advanced, metastatic or locally recurrent NSCLC	(TA347)	July 2015	Implemented at trust
136.	Bevacizumab Relapsed platinum resistant ovarian, fallopian tube or primary peritoneal ca.	(TA353)	August 2015	Appraisal terminated.
137.	Edoxaban Treatment and prevention of DVT & PE.	(TA354)	August 2015	Implemented at trust
138.	Pembrolizumab in advanced melanoma after disease progression with ipilimumab (& dabrafenib, vemurafenib & trametanib in BRAF VB600+ve patients)	(TA357)	October 2015	Implemented at trust
139.	Idelalisib in combination with rituximab as a possible treatment option for : a. untreated CLL (17p deletion of	(TA359)	October 2015	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

	TP53 mutation) b. CLL previously treated but has come back within 2 years. Clinical unit leads aware.			
140.	nabPaclitaxel in combination with gemcitabine in previously untreated metastatic pancreatic ca.	(TA360)	October 2015	Implemented at trust
141.	Pembrolizumab for advanced melanoma not previously treated with ipilimumab	(TA366)	November 2015	Implemented at trust
142.	Trastuzumab emtansine for treating HER2 (+ve) unresectable locally advanced or metastatic Breast ca. after treatment with trastuzumab and a taxane.	(TA371)	December 2015	Implemented at trust
143.	Erlotinib and gefitinib for treating NSCLC that has progressed on prior therapy.	(TA374)	December 2015	Implemented at trust
144.	Bortezomib for previously treated mantle cell lymphoma.	(TA370)	December 2015	Implemented at trust
145.	Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. In patients with no or mild symptoms after androgen deprivation therapy has failed	(TA377)	January 2016	Implemented at trust
146.	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy,	(TA381)	January 2016	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

	following 3 or more courses of platinum based chemotherapy			
147.	Panobinostat for treating multiple myeloma after at least 2 previous treatments	(TA380)	January 2016	Implemented at trust
148.	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases, following treatment with docetaxel	(TA376)	January 2016	Implemented at trust
149.	Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy	(TA378)	January 2016	Implemented at trust
150.	Myeloma: diagnosis and management	(NG35)	February 2016	Implemented at trust
151.	Nivolumab as a treatment option for advanced resectable melanoma	(TA384)	February 2016	Implemented at trust
152.	Topotecan, pegylated liposomal doxorubicin, paclitaxel, trabectedin & gemcitabine in recurrent ovarian ca. (replacing TA91 & TA222)	(TA389)	April 2016	Implemented at trust
153.	Abiraterone in metastatic hormone relapsed prostate ca. before chemo.	(TA387)	April 2016	Implemented at trust
154.	Canagliflozin, dapagliflozin & empagliflozin as monotherapies for treating type II diabetes	(TA390)	May 2016	Implemented at trust
155.	Cabazitaxel in HRPC post docetaxel	(TA391)	May 2016	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

156.	Ceritinib – in previously treated anaplastic lymphoma kinase +ve NSCLC (who have previously had crizotinib)	(TA395)	June 2016	Implemented at trust
157.	Trametanib & dabrafenib – unresectable or metastatic melanoma that has BRAF V600 mutation	(TA396)	June 2016	Implemented at trust
158.	Bosutinib in CML. Chronic, accelerated and blast phase (ph+ve)	(TA401)	August 2016	Implemented at trust
159.	Pemetrexed maintenance in NSNSCLC (after pemetrexed/cisplatin)	(TA402)	August 2016	Implemented at trust
160.	Ramucirumab in locally advanced NSCLC	(TA403)	August 2016	Implemented at trust
161.	Degarelix in advanced hormone dependent prostate ca (with spinal metastases)	(TA404)	August 2016	Implemented at trust
162.	Trifludine-tipiracil in previously treated metastatic	(TA405)	August 2016	Implemented at trust
163.	Crizotinib for untreated anaplastic lymphoma kinase +ve advanced non small cell lung cancer	(TA406)	September 2016	Implemented at trust
164.	Pegasparagase for treating acute lymphoblastic leukaemia (untreated and newly diagnosed)	(TA408)	September 2016	Implemented at trust
165.	Talimogene laherparepvec in unresectable metastatic melanoma when immunotherapies are not suitable	(TA410)	September 2016	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

166.	Radium – 223 in hormone relapsed prostate cancer (with no known visceral metastases)	(TA412)	September 2016	Implemented at trust
167.	Necitimumab for untreated advanced or metastatic squamous NSCLC (in combination with gemcitabine & cisplatin).	(TA411)	September 2016	Implemented at trust
168.	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma	(TA414)	October 2016	Implemented at trust
169.	Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (via CDF)	(TA416)	October 2016	Implemented at trust
170.	Nivolumab in advanced renal cell carcinoma (+ve).	(TA417)	November 2106	Implemented at trust
171.	Everolimus with exemestane fro advanced breast ca.	(TA421)	December 2016	Implemented at trust
172.	Crizotinib for previously treated anaphylactic lymphokinase	(TA422)	December 2016	Implemented at trust
173.	Eribulin fro locally advanced or metastatic breast ca.	(TA423)	December 2016	Implemented at trust
174.	Pertuzumab in neoadjuvant HER2+ve Breast ca.	(TA424)	December 2016	Implemented at trust
175.	Dasatinib, nilotinib & HD imatinib in resistant/intolerant CML	(TA425)	December 2016	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

176.	Dasatinib, nilotinib & imatinib in untreated CML	(TA426)	December 2016	Implemented at trust
177.	Pomalidomide in MM previously treated with lenalidomide & bortezomib	(TA427)	January 2017	Implemented at trust
178.	Pembrolizumab for PDL1 +ve NSCLC (after chemotherapy)	(TA428)	January 2017	Implemented at trust
179.	Ibrutinib in previously treated CLL.	(TA429)	January 2017	Implemented at trust
180.	Everolimus for advanced RCC (after previous treatment). James Larkin aware of guidance.	(TA432)	February 2017	Implemented at trust
181.	Cetuximab & panitumumab for previously untreated mCRC (RAS wild type) in combination with FOLFOX/FOLFIRI	(TA439)	March 2017	Implemented at trust
182.	Nanoliposomal irinotecan for pancreatic ca. after gemcitabine (metastatic adeno ca.)	(TA440)	April 2017	Implemented at trust
183.	Brentuximab for treating CD30+ve	(TA446)	June 2017	Implemented at trust
184.	Pembrolizumab for untreated PDL1 +ve metastatic NSCLC	(TA447)	June 2017	Implemented at trust
185.	Blinatumumab in Ph+ve ALL	(TA450)	June 2017	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

186.	Ponatinib in CML & ALL	(TA451)	June 2017	Implemented at trust
187.	Carfilzomib for previously treated MM	(TA457)	July 2017	Implemented at trust
188.	Trastuzumab emtansine for HER2+ advanced Breast ca.	(TA458)	July 2017	Implemented at trust
189.	Nivolumab in relapsed/refractory HL	TA462	July 2017	Implemented at trust
190.	Cabozantinib in advanced RCC (post VEGF therapy)	TA463	August 2017	Implemented at trust
191.	Olaratumumab in combination with doxorubicin in STS	TA465	August 2017	Implemented at trust
192.	Obinutuzumab plus bendamustine in follicular lymphoma	TA472	August 2017	Implemented at trust
193.	Cetuximab in recurrent metastatic squamous cell ca.	TA473	August 2017	Implemented at trust
194.	Pemetrexed maintenance in advanced NSCLC	TA190	August 2017	Implemented at trust
195.	Sorafenib in advanced hepatocellular ca.	TA474	September 2017	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

196.	Abraxane plus gemcitabine in untreated metastatic pancreatic ca.	TA476	September 2017	Implemented at trust
197.	Relapsed refractory systematic anaplastic large cell lymphoma (ECOG 0-1)	TA 478	October 2017	Implemented at trust
198.	Nivolumab in previously treated NSCLC	TA483	November 2017	Implemented at trust
199.	Venetoclax in CLL	TA487	November 2017	Implemented at trust
200.	Regorafenib in previously treated or unresectable GIST	TA488	November 2017	Implemented at trust
201.	Vismodogib in basal cell carcinoma	TA489	November 2017	Implemented at trust
202.	Ibrutinib in Waldenstroms Macroglobulinaemia	TA491	November 2017	Implemented at trust
203.	Atezolizumab in untreated locally advanced or metastatic urothelial cancer	TA492	December 2017	Implemented at trust
204.	Palbociclib with an AI for previously untreated HR+ve , HER-ve, locally advanced/metastatic Breast ca.	TA495	January 2018	Implemented at trust
205.	Ribociclib with an AI for previously untreated HR+ve , HER-ve, locally advanced/metastatic Breast ca.	TA496	January 2018	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

206.	Lenvatinib with everolimus for previously treated advanced renal cell carcinoma	TA498	February 2018	Implemented at trust
207.	Ceritinib for untreated ALK-positive advanced non-small-cell lung cancer	TA500	February 2018	Implemented at trust
208.	Intrabeam radiotherapy system for adjuvant treatment of early breast cancer	TA501	February 2018	Not used at the trust
209.	Ibrutinib for treating relapsed or refractory mantle cell lymphoma only if they have had only 1 previous line of therapy	TA502	February 2018	Implemented at trust
210.	Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer	TA503	February 2018	Implemented at trust
211.	Ixazomib with lenalidomide and dexamethasone for treating Relapsed Refractory Multiple Myeloma.	TA505	February 2018	Implemented at trust
212.	Pertuzumab & Trastuzumab & Docetaxel in HER2+ve Breast ca.	TA509	March 2018	Implemented at trust
213.	Daratumumab (monotherapy) relapsed refractory Multiple Myeloma	TA510	March 2018	Implemented at trust
214.	Tivozanib for treating advanced RCC (no prior treatments)	TA512	March 2018	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

215.	Obinotuzumab for untreated advanced follicular lymphoma (FLIPI score of 2 or more)	TA513	March 2018	Implemented at trust
216.	Regorafenib for previously treated advanced hepatocellular carcinoma	TA514	March 2018	Implemented at trust
217.	Eribulin in locally advanced breast ca (replacing TA250)	TA515	March 2018	Implemented at trust
218.	Cabozantinib for treating progressive medullary thyroid cancer (unresectable, advanced or metastatic	TA516	March 2018	Implemented at trust
219.	Avelumab for treating metastatic merkel cell carcinoma following 1 or more lines of chemotherapy	TA517	April 2018	Implemented at trust
220.	Pembrolizumab for locally advanced or metastatic urothelial carcinoma after platinum containing chemotherapy	TA518	April 2018	Implemented at trust
221.	Atezolizumab for treating locally advanced or metastatic NSCLC post chemo or EGFR/ALK +ve	TA520	May 2018	Implemented at trust
222.	Pembrolizumab in untreated locally advanced or metastatic urothelial ca. when cisplatin is unsuitable	TA522	June 2018	Implemented at trust
223.	Midostaurin in newly diagnosed FLT3+ve myeloid leukemia	TA523	June 2018	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

224.	Brentuximab for CD30+ve Hodgkin Lymphoma (relapsed/refractory) (TA524)		June 2018	Implemented at trust
225.	Atezolizumab for treating locally advanced or metastatic urothelial carcinoma	TA525	June 2018	Implemented at trust
226.	Arsenic trioxide in APL (including remission and consolidation)	TA526	June 2018	Implemented at trust
227.	Niraparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian tube and peritoneal ca.	TA528	July 2018	Implemented at trust
228.	Crizotinib for treating ROS1 +ve advanced NSCLC	TA529	July 2018	Implemented at trust
229.	Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum containing chemotherapy	TA530	July 2018	Implemented at trust
230.	Pembrolizumab for untreated PDL1 +ve metastatic NSCLC	TA531	July 2018	Implemented at trust
231.	Alectinib for untreated ALK+ve advanced NSCL	TA536	August 2018	Implemented at trust
232.	Lenvatinib & sorafenib for treating differentiated thyroid ca. after radioactive iodine	TA535	August 2018	Implemented at trust
233.	Dinutuximab beta for treating	TA538	August 2018	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

234.	Lutetium Oxodotreotide for treating unresectable or metastatic neuroendocrine	TA539	August 2018	Implemented at trust
235.	Pembrolizumab for treating relapsed or refractory classical HL following brentuximab not eligible for auto transplant	TA540	September 2018	Implemented at trust
236.	Inotuzumab ozogamicin for relapsed/refractory B cell acute lymphoblastic leukaemia	TA541	September 2018	Implemented at trust
237.	Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation +ve melanoma	TA542	October 2018	Implemented at trust
238.	Cabozantinib for untreated advanced RCC	TA544	October 2018	Implemented at trust
239.	Gemtuzumab for untreated AML (plus daunorubicin and cytarabine)	TA545	November 2018	Implemented at trust
240.	Padeliporfin in localised prostate ca	TA546	November 2018	Implemented at trust
241.	Vandetanib in medullary thyroid ca.	TA550	December 2018	Implemented at trust
242.	Regorafenib for previously treated hepatocellular ca. following sorafenib	TA555	January 2019	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

243.	Pembrolizumab plus pemetrexed and platinum chemotherapy for untreated metastatic NSCLC	TA557	January 2019	Implemented at trust
244.	Nivolumab for adjuvant treatment of resected melanoma with lymph node involvement or metastatic disease	TA558	January 2019	Implemented at trust
245.	Axicabatgene for treatemt of diffuse large B-cell lymphoma following two plus lines of systemic therapy	TA559	January 2019	Implemented at trust
246.	Venetoclax with rituximab for previously treated CLL	TA561	February 2019	Implemented at trust
247.	Encorafenib with binimetinib for unresectabel or metastatic BRAFV600 mutation +ve melanoma	TA562	February 2019	Implemented at trust
248.	Abemaciclib & aromatase inhibitor for previously untreated HR+ve HER2-ve locally advanced or metastatic	TA563	February 2019	Implemented at trust
249.	Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma (TA567)	TA563	March 2019	Implemented at trust
250.	Pertuzumab for adjuvant treatment of HER2+ve early stage breast ca.	TA569	March 2019	Implemented at trust
251.	Brigatinib for ALK+ve advanced NSCLC after crizotinib	TA571	March 2019	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

252.	Brentuximab in CD30 +ve Tcell Lymphoma (after 1 systemic treatment)	TA577	April 2019	Implemented at trust
253.	Daratumumab in combination with bortezomib & dexamethasone in relapsed	TA573	April 2019	Implemented at trust
254.	Durvalumab for treating locally advanced unresectable NSCLC	TA578	May 2019	Implemented at trust
255.	Abemaciclib with fulvestrant in HER2-ve Breast ca.	TA579	May 2019	Implemented at trust
256.	Enzalutamide in High risk non-metastatic Breast ca.	TA580	May 2019	Implemented at trust
257.	Nivolumab in combination with Ipilimumab for untreated RCC	TA581	May 2019	Implemented at trust
258.	Atezolizumab in combination with bevacizumab, carboplatin & paclitaxel) in metastatic non squamous NSCLC	TA584	June 2019	Implemented at trust
259.	Lenalidomide in combination with dexamethasone in MM 1 year post bortezomib treatment (TA586)	TA587	June 2019	Implemented at trust
260.	Lenalidomide in combination with dexamethasone for previously untreated MM	TA588	June 2019	Implemented at trust
261.	Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual	TA589	July 2019	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

	disease activity			
262.	Letermovir for preventing cytomegalovirus disease after a stem cell transplant	TA591	July 2019	Implemented at trust
263.	Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma	TA592	August 2019	Implemented at trust
264.	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	TA593	August 2019	Implemented at trust
265.	Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer	TA595	August 2019	Implemented at trust
266.	Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer	TA598	August 2019	Implemented at trust
267.	Idelalisib in refractory follicular lymphoma	TA604	October 2019	Implemented at trust
268.	Rucaparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian or peritoneal ca.	TA611	November 2019	Implemented at trust
269.	Pentosan polysulfate sodium for treating bladder pain syndrome	TA610	November 2019	Implemented at trust

The Royal Marsden NHS Foundation Trust – Medicines Formulary

270.	National Guidance; Cannabis based medicinal products.	NG144	November 2019	Implemented at trust
271.	Palbociclib & fulvestrant in HR+ve, HER2-ve Breast ca.	TA619	January 2020	Implemented at trust
272.	Olaparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian & peritoneal ca.	TA620	January 2020	Implemented at trust
273.	Osimertinib for untreated EGFR+ve NSCLC	TA621	January 2020	Implemented at trust
274.	Lenalidomide with rituximab for previously treated follicular lymphoma (grade 1-3a)	TA627	April 2020	Implemented at trust
275.	Lorlatinib for previously treated ALK+ve advanced NSCLC	TA628	May 2020	Implemented at trust
276.	Obinatuzumab with bendamustine for treating follicular lymphoma	TA629	May 2020	Implemented at trust
277.	Larotrectinib for treating NTRK fusion +ve solid tumours (refer to guidance in relation to phased introduction)	TA630	May 2020	Implemented at trust
278.	Trastuzumab emtansine for adjuvant HER2+ve early Breast ca.	TA632	June 2020	Implemented at trust